Literature DB >> 1367214

High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells.

M J Page1, M A Sydenham.   

Abstract

We have cloned the light and heavy chain cDNAs for the humanized monoclonal antibody Campath-1H and expressed them in Chinese hamster ovary (CHO) cells using a dihydrofolate reductase (dhfr) amplification procedure. Each cDNA was positioned under control of the strong human beta-actin promoter/polyadenylation signals and used to evaluate alternative vector design and amplification procedures. By employing a dual selection co-transfection strategy, initial transformants accumulated antibody levels of 0.5 micrograms/ml after 4 days continuous culture. When subjected to successive rounds of selection in medium containing stepwise increments in methotrexate (MTX), stable cell lines were obtained that secreted up to 200 micrograms/ml of Campath-1H during the same period. This reflects a productivity of 100 micrograms/10(6) cells/day and demonstrates the potential of engineering CHO cells for the production of recombinant antibodies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1367214     DOI: 10.1038/nbt0191-64

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN: 0733-222X


  23 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells.

Authors:  J Berdoz; C T Blanc; M Reinhardt; J P Kraehenbuhl; B Corthésy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  Genetic engineering of α2,6-sialyltransferase in recombinant CHO cells and its effects on the sialylation of recombinant interferon-γ.

Authors:  L Monaco; A Marc; A Eon-Duval; G Acerbis; G Distefano; D Lamotte; J M Engasser; M Soria; N Jenkins
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

4.  Reshaping a therapeutic CD4 antibody.

Authors:  S D Gorman; M R Clark; E G Routledge; S P Cobbold; H Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

5.  Taq DNA polymerase extension of internal primers blocks polymerase chain reactions allowing differential amplification of molecules with identical 5' and 3' ends.

Authors:  A P Lewis; M J Sims; D R Gewert; T C Peakman; H Spence; J S Crowe
Journal:  Nucleic Acids Res       Date:  1994-07-25       Impact factor: 16.971

6.  Unaltered immunoglobulin expression in hybridoma cells modified by targeting of the heavy chain locus with an integration vector.

Authors:  R Mocikat; C Kardinal; P Lang; R Zeidler; S Thierfelder
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

7.  Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.

Authors:  J R Salisbury; N T Rapson; J D Codd; M V Rogers; A B Nethersell
Journal:  J Clin Pathol       Date:  1994-04       Impact factor: 3.411

Review 8.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Production of anti TNF-α antibodies in eukaryotic cells using different combinations of vectors carrying heavy and light chains.

Authors:  Dmitriy Balabashin; Elena Kovalenko; Viktoria Toporova; Teimur Aliev; Anna Panina; Elena Svirshchevskaya; Dmitry Dolgikh; Mikhail Kirpichnikov
Journal:  Cytotechnology       Date:  2014-06-18       Impact factor: 2.058

10.  Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material.

Authors:  J S Crowe; V S Hall; M A Smith; H J Cooper; J P Tite
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.